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Mycobacterium 
tuberculosis Beijing 
Strain, Bamako, 
Mali
To the Editor:  Mycobacterium 
tuberculosis has >36 identiﬁ  ed geno-
type families (1). Four genotypes 
cause 35% of documented cases of ac-
tive tuberculosis (TB): Beijing (10%–
11%), Latin American–Mediterranean 
(9.3%), Haarlem (7.5%), and the X 
clade (7%) (1,2) The Beijing clade 
strains, reported in 1995 from the Peo-
ple’s Republic of China, are widely 
recognized as highly pathogenic with 
a possible predilection for multidrug 
resistance (3). Predominant in Asia, 
these strains have been documented 
in other parts of the world (1,4,5). The 
virulence, propensity to become re-
sistant, and distinct geographic distri-
bution of the Beijing clade suggest it 
may have some adaptive advantage in 
producing disease in humans. Limited 
data suggest that its presence in Africa 
is low (2,4,5).
In Bamako, Mali, 2 patients with 
active pulmonary TB came to the re-
search clinic at Point G Hospital, af-
ﬁ  liated with the University of Bamako 
Medical School, for recruitment un-
der a US National Institute of Allergy 
and Infectious Diseases’ institutional 
review board–approved protocol. The 
ﬁ   rst patient,  a previously healthy 
34-year-old man, sought treatment 
in March 2008. He had a 3-month 
history of fever, cough, shortness 
of breath, and left-sided chest pain; 
respiratory rate of 24/min; tempera-
ture of 36.8ºC; and pulse rate of 68/
min. He weighed 60 kg. His leuko-
cyte count was 8,700 cells/μL, and he 
was positive for HIV-1 with a CD4+ 
T-cell count of 468 cells/μL. He re-
ported contact with persons from 
other countries in Africa, China, and 
other parts of Asia.
Chest radiograph showed a cavi-
tary lesion on the left upper lobe and 
opacities throughout the left lung. 
Three sputum samples collected 3 
days apart were digested and decon-
taminated with N-acetyl-L-cysteine, 
4% NaOH; concentrated by high-
speed centrifugation; stained with 
auramine-rhodamine; and evaluated 
by using ﬂ  uorescent microscopy. The 
many acid-fast bacilli (AFB) seen 
were identiﬁ  ed by using nucleic acid 
probes (AccuProbe, Gen-Probe, San 
Diego CA, USA). Antimycobacterial 
drug susceptibility was determined by 
using a manual indirect susceptibility 
test (mycobacterial growth indicator 
tube, AST SIRE System; BBL, Bec-
ton Dickinson, Franklin Lakes, NJ, 
USA) showed the isolate sensitive to 
isoniazid (0.1 μg/mL), rifampin (1.0 
μg/mL), and ethambutol (3.5 μg/mL) 
but resistant to streptomycin (0.8 μg/
mL). Spoligotyping using a commer-
cially available kit (Spoligotyping 
Isogen Life Science, De Meern, the 
Netherlands) showed characteristics 
of the Beijing clade (online Appendix 
Figure, panel A, www.cdc.gov/EID/
content/16/2/362-appF.htm) (6).
The patient began treatment with 
the standard ﬁ  rst-line regimen of iso-
niazid, rifampin, pyrazinamide, and 
ethambutol  ﬁ  xed-dose  combination 
(Svizera Laboratory, Mumbai, India) 
according to Malian National Guide-
lines. Follow-up sputum samples at 
13 and 18 weeks of treatment were 
smear- and culture-negative for AFB.
The second patient, a 28-year-
old woman, sought treatment in July 
2008. For 1 year, she had received 
ﬁ   rst-line and retreatment regimens 
that failed to clear her sputum of 
AFB. She had begun second-line 
treatment for multidrug-resistant 
disease 2 days earlier. She had a his-
tory of fever, cough, and weight loss; 
temperature of 37.1ºC; heart rate of 
104 beats/min; respiratory rate of 24/
min; and blood pressure of 90/60 Hg 
mm. She weighed 49 kg. Leukocyte 
count was 9,400 cells/μL. Serologic 
results for HIV-1 and -2 were nega-
tive. Chest radiograph showed a right 
apical cavitary lesion and a ﬁ  brotic 
lesion in the right middle lung ﬁ  eld. 
She did not recall any exposure to 
TB. She worked as an assistant at a 
local telephone center.
Two sputum samples, processed 
as described above, were positive for, 
and Gen-Probe testing conﬁ  rmed, M. 
tuberculosis. According to antimy-
cobacterial susceptibility testing, the 
strain was resistant to isoniazid (0.1 
μg/mL), rifampin (1.0 μg/mL), etham-
butol (3.5 μg/mL), and streptomycin 
(0.8 μg/mL). Spoligotyping conﬁ  rmed 
the strain as Beijing clade, and restric-
tion fragment length polymorphism 
(7) conﬁ  rmed that it differed from that 
of patient 1 (online Appendix Figure, 
panel B).
The relevance of different geno-
types, such as the Beijing clade, to 
disease progression is being stud-
ied. Evidence indicates the genotype 
may factor in transmission or patho-
genesis. In a study in Cape Town, 
South Africa, disease produced by 
the Beijing clade increased exponen-
tially over time, suggesting a possible 
pathogenic advantage; although most 
cases were drug susceptible, the like-
lihood of unsuccessful treatment was 
greater than for non-Beijing variants 
(8). Although the Beijing clade does 
not appear to have greater propen-
sity than non-Beijing genotypes for 
acquiring resistance, certain variants 
within the group that become mul-
tidrug resistant may be more likely 
to acquire such resistance. Beijing 
strains particularly may tend to ac-
quire resistance more easily than oth-
ers under conditions of suboptimal 
treatment (9). In Cape Town during 
2000–2003, the Beijing clade as a 
cause of disease in children increased 
from 13% to 33%, suggesting a selec-
tive advantage in transmissibility and 
disease production (10).
These cases highlight the need to 
diagnose disease and resistance early 
and to begin appropriate treatment in 
TB-endemic countries. Knowledge of 
circulating strains and their resistance 
patterns is essential to developing 
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effective programs to curtail the 
spread of TB within the country and 
the region; in this era of globalization, 
it is required for the successful control 
of TB worldwide.
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Hemorrhagic Fever 
with Renal 
Syndrome, Vietnam
To the Editor: Hantaviruses are 
primarily rodent borne and can cause 
hemorrhagic fever with renal syndrome 
(HFRS) in persons who inhale aero-
solized excreta from infected rodents. 
The clinical characteristics of HFRS 
are fever, hemorrhage, and varying de-
grees of renal and hepatic dysfunction. 
Although HFRS is endemic primarily 
to Eurasian regions, there is serologic 
evidence of hantavirus infections in 
rodents and humans worldwide (1). 
Little is known about the occurrence 
of hantavirus infection in rodents or 
humans in Vietnam. One study found 
5.4% prevalence of antibodies against 
Hantaan 76–118 and Puumala strains 
among residents of the Hanoi Metro-
politan (2), whereas another study in 
southern Vietnam did not ﬁ  nd evidence 
of hantavirus infection in humans (3). 
We describe autochthonous HFRS 
from Vietnam, possible reservoir hosts, 
and the follow-up investigation, which 
implies the presence of a strain of Seoul 
virus (SEOV).
The case-patient was a previously 
healthy 25-year-old nurse working in a 
referral hospital and residing in a semi-
urban district of Ho Chi Minh City. On 
September 23, 2008, she was admitted 
to the referral hospital with a history 
of high fever, chills, myalgia, nausea, 
vomiting, hematuria, and abdomi-
nal and lower back pain for 3 days. 
Physical examination showed a body 
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